2023 - Cancer Currents Blog
-
A new study has compared three formulations of an mRNA vaccine designed to treat cancers caused by human papillomavirus (HPV) infections. All three vaccines showed promise in mice.
-
The high cost of cancer care can cause added distress and life disruptions for patients as well as their loved ones. Researchers at the University of Kentucky Markey Cancer Center found that a financial navigation program saved patients and their loved ones an average of about $2,500 each.
-
Treatment with revumenib caused complete remission in about one-third of participants in an early-phase clinical trial involving patients who’d had many prior treatments. Revumenib is part of a new class of targeted drugs known as menin inhibitors.
-
In this Q&A, NCI Director Dr. Monica Bertagnolli and Deputy Director for Clinical and Translational Research Dr. James Doroshow explain the challenges of cancer clinical trials and important steps NCI is taking to improve their effectiveness.
-
In two clinical trials, combining immune checkpoint inhibitors with standard chemotherapy substantially increased how long people with advanced endometrial cancer lived without their cancer worsening, particularly those with dMMR or MSI-high tumors.
-
Results from a new study highlight the progress being made toward developing liquid biopsies specifically for use in children with solid cancers like Ewing sarcoma and Wilms tumor. The tests can help detect and diagnose cancer and monitor for response to treatment and recurrence.
-
The consequences of climate change have already affected cancer care in the United States, particularly in areas hit by hurricanes and wildfires. Researchers are studying how to mitigate that impact and better understand the effect of climate change on the risk of developing cancer.